4.10.25.5Vertical

Rheumatology Management Organizations

PE-backed platforms consolidating rheumatology practices.

Market snapshot

These figures describe Rheumatology (4.10.25), the segment that Rheumatology Management Organizations sits within — not Rheumatology Management Organizations on its own.

FragmentationConsolidatingEstimate

Within Offices of Physicians (NAICS 621111); the Census Bureau does not split physician offices by specialty, so rheumatology is not separately sized.

Business model & economics

Revenue model

Office reimbursement plus in-office biologic infusion margin

Key economics

Recurring revenue
High

chronic autoimmune care and infusion

EBITDA margin
18–28% with infusion ancillaries
Capex intensity
Low

Characteristics

  • In-office biologic infusion drives ancillary economics.
  • Autoimmune prevalence and biologics growth.
  • Rheumatologist shortage and emerging MSO interest.

M&A deal context

Deal activityModerate

Who’s acquiring

  • Infusion-focused MSO platforms
  • PE-backed rheumatology consolidators
  • Multispecialty acquirers

What’s driving deals

  • Roll-up for infusion ancillary economics.
  • Autoimmune and biologics demand.
  • Rheumatologist shortage.

Find Rheumatology Management Organizations acquisition targets

Search Acquisera’s index for companies classified under Rheumatology Management Organizations (4.10.25.5) and build a targeted deal pipeline.

Search companies